Axis of Endocrinology · Mar 17, 2026

Statins and safety: an evidence-based assessment of common beliefs about adverse effects with a focus on endocrinology practice

By Викторович ХМ, Мартиросян НС, Петунина Н

Statins remain the mainstay of pharmacotherapy for reducing concentrations of total cholesterol and low-density lipoproteins, as well as for preventing atherosclerotic cardiovascular disease. Despite proven efficacy, statin prescribing and long-term use are often limited by reduced patient adherence and clinical doubts among treating physicians, largely attributable to persistent beliefs about toxicity and the erroneous establishment of a causal relationship between the use of drugs in this class and nonspecific symptoms. This topic is particularly important for endocrinologists because patients with type 2 diabetes mellitus, obesity, metabolic dysfunction-associated fatty liver disease, and age-related hormonal changes are at increased cardiovascular risk and more frequently receive statins. This review systematizes data from large randomized clinical trials, meta-analyses, and high-quality observational cohort studies on the most common misconceptions, including liver injury, the risk of cirrhosis and hepatocellular carcinoma, increased risk of diabetes mellitus, effects on sex hormones, cognitive outcomes, and statin-associated muscle symptoms. The contribution of the nocebo effect and risk factors for true myopathy are discussed separately. A practical algorithm for managing patients with suspected adverse events is proposed. Statins remain the cornerstone pharmacotherapy for lowering total cholesterol and low-density lipoprotein cholesterol and for preventing atherosclerotic cardiovascular disease. Despite well-established efficacy, statin initiation and long-term persistence are frequently limited by reduced patient adherence and clinicians’ uncertainty, largely driven by persistent beliefs about toxicity and by erroneous attribution of nonspecific symptoms to statin therapy. This issue is particularly relevant to endocrinologists because patients with type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease and age-related hormonal changes carry elevated cardiovascular risk and are more likely to receive statins. This review synthesizes evidence from large randomized controlled trials, meta-analyses, and high-quality observational cohort studies addressing the most prevalent misconceptions, including hepatic injury, risks of cirrhosis and hepatocellular carcinoma, incident diabetes, effects on sex hormones, cognitive outcomes, and statin-associated muscle symptoms. The role of the nocebo effect and risk factors for true statin-induced myopathy are discussed, and a practical management algorithm is proposed for patients with suspected adverse effects.

doi.org/10.46393/30337380_2026_1_18-24Interventions

AgingResearch.News